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X-ray Crystallographic and Functional Characterization of BshC:
The Third Step of Bacillithiol Biosynthesis
Andrew VanDuinen*, and Paul D. Cook*
Department of *Cell & Molecular Biology, Grand Valley State University, Allendale, MI

Abstract
Bacillithiol is a low molecular weight thiol that reduces oxidative stress and regulates thiol
homeostasis in some Gram-positive bacteria, including the pathogenic Bacillus anthracis and
Staphylococcus aureus. It has recently been determined that bacillithiol plays a key role in
resistance to the FDA-approved antibiotic fosfomycin. The biosynthesis of BSH is believed to
occur via a three step pathway utilizing the enzymes BshA, BshB, and BshC. BshA replaces
UDP with malate on UDP-N-acetylglucosamine. BshB acts as a deacetylase to produce
glucosaminyl-malate, and BshC is proposed to add cysteine to glucosaminyl-malate to produce
bacillithiol. The first solved structure of BshC from Bacillus subtilus contains three key domains
of interest. The first is the active site which putatively adds a cysteine to glucosaminyl-malate.
The coiled-coil portion forms a tail-like projection that allows dimerization and is a highly
conserved region. The third domain of interest contains an ADP molecule. The function of this
domain is highly uncertain, and the amino acid residues are not highly conserved among BshC
from various species. PHYRE2 was be used to generate a hypothetical model of BshC from S.
aureus. The BshC gene was isolated from S. aureus genomic DNA. After expressing and
isolating the protein, protein crystals will be analyzed via x-ray crystallography to gain insight
into the different domains of interest. Functional analysis of BshC will also be pursued to clue
into the mechanism dictating its activity. Understanding how BshC functions will allow specific
inhibitors to be designed to stop bacillithiol biosynthesis and re-establish fosfomycin as an
effective antibiotic once again.

Background and Context
Bacillithiol Cells in an oxidative environment can produce free radicals that damage the
cell. For this reason, low molecular weight thiols form disulfide bonds that protect the cell from
oxidation. The major low molecular weight thiols include glutathione (GSH), which is found in
Gram-negative bacteria, mycothiol (MSH), found in some Gram-positive bacteria, and the
recently identified bacillithiol (BSH), also found in Gram-positive bacteria.1 Bacillithiol (BSH)
is classified as a low molecular weight thiol that reduces oxidative stress and regulates thiol
homeostasis. It is also capable of detoxifying foreign compounds. BSH is present in many
species of Bacillus including B. anthracis, B. subtilis, B. megaterium, and is also observed
in Staphylococcus aureus.2 The biosynthesis of BSH is similar to the established pathway of
MSH. Using the MSH pathway as a guide, the biosynthesis of BSH was predicted to require
three enzymes, BshA, BshB, and BshC in the three step biosynthetic pathway shown in
Scheme1.1 BshA utilizes malate and UDP-N-acetylglucosamine to produce Nacetylglucosamine-malate. BshB converts this to glucosamine-malate, and BshC putatively acts
as a cysteinyl ligase to convert glucosamine-malate to bacillithiol.

Scheme 1. Bacillithol biosynthesis pathway.
BSH and Fosfomycin Fosfomycin tromethamine is effective in treating pathogenic
Escherichia coli, Citrobacter, Enterobacter, Klebsiella, Serratia, and Enterococcus spp. Taken
as a three gram oral dose, it effectively treats urinary tract infections caused by the latter

bacteria.3 Fosfomycin has also been used in combination with other antibiotics to treat the
biofilm formation of methicillin-resistant Staphylococcus aureus (MRSA).4 Bacillithiol can form
disulfide bonds between thiols and act as a buffer against alkylating compounds or electrophiles.1
The FosB enzyme adds BSH to destroy the epoxide ring of fosfomycin conferring resistance to it
as depicted in Scheme 2.5 Evidence strongly supports BSH as the preferred substrate for this
phenomenon.6

Scheme 2. Destruction of fosfomycin by FosB utilizing BSH
When the gene encoding BshA, BshB, or BshC is knocked out, BSH production is eliminated;
the cell once again becomes sensitive to the antibiotic fosfomycin.7 Because of this, inhibitors to
any enzyme in the BSH biosynthetic pathway could be designed to re-establish fosfomycin’s
effectiveness as an antibiotic.
MshC Mechanism. The MshC enzyme from the evolutionarily related mycothiol
biosynthetic pathway acts as an ATP-dependent cysteinyl ligase. The intermediate forms an EAMP-cysteine complex. Prior to binding to the enzyme, ATP binds to cysteine creating an
activated cysteine-AMP complex in the active site which then donates cysteine to glucosaminylmalate.8 While BshC has not shown ATP-dependence in in vitro studies and has little overlap of
amino acid sequence with MshC, the similar Rossmann fold structure of B. subtilus BshC to
MshC presumably suggests that BshC in fact does function through an activated intermediate
complex.

Figure 1. BshC Overall Structure BshC has a core Rossmann fold domain, a coiled-coil tail,
connecting peptide region one (CP1), and a connecting peptide region two (CP2).
BshC Structure The overall structure of BshC is depicted in Figure 1. The core
Rossmann fold (blue) consists of a beta sheet flanked by two alpha helices. Rosmann folds are
able to bind nucleotides and are found in other cysteine ligases such as MshC. The connecting
peptide regions flank the core Rossmann fold (green and orange). A unique alpha helical coiledcoil domain (red) projects out as a tail in the monomeric structure.9
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Figure 2. ConSurf Analysis of BshC. Dark blue indicates highly conserved amino acid residues
among species. White area indicates amino acid residues not highly conserved among species.

BshC protein from B. subtilis overlaid with top BLAST hits in ConSurf shows areas of
highly conserved amino acid residues and structure in darker blue and less conserved areas in
white. The active site domain is highly conserved among species that produce BSH as shown in
Figure 2A by dark blue in the pocket surrounding citrate and glycerol. The coiled-coil domain of
BshC, represented as a tail like projection in Figure 2C, also depicts high sequence conservation
among species. The domain binding ADP in Figure 2B, however, shows a domain not highly
conserved between species as it is lighter blue and more gray. Based on these observations, it is
unclear as to whether BshC from other Gram positive species bears amino acid residues that bind
ADP in a similar manner as B. subtilis BshC does.9
In order for a drug to be designed that would be able to bind in the active site and inhibit
BshC activity, more information about the active site amino acid residues and the ADP binding
pocket is required. A PHYRE2 model was used to establish a hypothetical structure of BshC
from S. aureus. Protein crystals will be grown to test this hypothetical structure using x-ray
crystallography to enable characterization of S. aureus BshC. Functional analysis of BshC was
also executed to understand more about the mechanism of its activity. Expanding understanding
of the enzyme’s structure and function, and the role of ADP in this, will aid in characterizing
drugs that inhibit bacillithiol biosynthesis.

Materials and Methods
Overview
PHYRE2 was used to predict the structure of S. aureus BshC. To determine the actual structure,
the BshC gene was first isolated from Staphylococcus aureus genomic DNA. The T7 expression
system was used to overexpress BshC protein production using IPTG. The S. aureus BshC
protein was then purified by Ni-NTA affinity chromatography utilizing the his-tag with solubility
and purity being assessed by SDS-PAGE. Pure protein was used to set up crystallization screens
and perform functional analysis of BshC.

PHYRE2 Structural Alignment
Protein Homology/Analogy Recognition Engine V 2.0 (PHYRE2) was used to map predict a
conformational structure of BshC from S. aureus based on the known structure of BshC from B.
subtilus.
Isolation of BshC gene from Staphylococcus aureus genomic DNA.
The BshC gene from S. aureus was isolated from total genomic DNA by designing primers 120
and 121 that flank the gene and only replicate BshC in a polymerase chain reaction (PCR). The
designed primers contained NheI and XhoI restriction cut sites on their ends so that the isolated
gene could be easily manipulated and inserted into the pET-28 expression plasmid. After
reconstituting the lyophilized primers and genomic DNA, a 50 uL PCR reaction with 0.5
pmol/uL of each primer and 100 ng of gDNA was carried out with Phusion DNA polymerase
from NEB. The result was visualized by agarose gel electrophoresis. DNA was isolated from the
gel band by using the GeneJET PCR Purification Kit and DNA concentration determined to be
181ng/uL.
Digestion and Ligation of DNA
Digestion of the PCR DNA with XhoI and NheI was performed with 3.62 ug of DNA so DNA
could be ligated into a vector. BshC was ligated into the pET-28 vector using 50 ng of insert and
50 ng of vector in a 10 uL reaction.
E. coli Transformation
About 50 µL of chemically competent Escherichia coli cells of the XL-1blue expression strain
were incubated on ice with 0.5-4 µL of the BshC pET-28 vector. The mixture rested on ice 10
minutes and was heat shocked at 42°C for 90 seconds. After resting on ice for 6 minutes, the
cells were allowed to recover with 250 µL of LB shaking at 200 RPM at 37°C for 1 hour and
subsequently plated on LB media containing 25 mg/mL of kanamycin and grown overnight at
37°C.

DNA isolation and Plasmid Digestion
After picking six individual transformed colonies and growing each of them in 5mL of LB
overnight, the BshC pET-28 vector was isolated by miniprepping with Thermo Scientific Gene
JET Plasmid Miniprep Kit. To confirm the BshC gene was successfully inserted into the plasmid
vector, a digestion with NheI and XhoI restriction enzymes was performed on 7 uL of each
plasmid and examined by agarose gel electrophoresis. After the BshC gene was shown to be
ligated in on an agarose gel, the plasmid was sequenced at the University of Michigan DNA
Sequencing Core facility to ensure it was the actual BshC inserted as expected.
Plasmid Propagation
In order to produce more S. aureus BshC plasmid DNA for use, 50 µL of the XL-1Blue
expression strain of E. coli cells were added to 0.5 µL of 35 ng/µL BshC S. aureus in pET-28.
After resting on ice for ten minutes, the cells were heat shocked at 42°C for 90 seconds and
immediately moved to ice for six minutes. Then, 250 µL of LB media was added and the tube
shaken at 37°C for 45 minutes. After this, the cells were plated onto a 25 mg/mL kanamycin LB
agar plate and grown overnight at 37°C. An individual colony was picked and placed in a sterile
culture tube containing 7 mL of LB media and 0.25 µg/mL kanamycin. Four of these tubes were
shaken at 200 RPM, 37°C overnight. The next day, the cells were pelleted and miniprepped
using a Thermo Scientific Molecular Biology GeneJET plasmid miniprep kit. The DNA
concentration and purity were determined via A260 utilizing a Thermo Scientific Nanodrop
Spectrophotometer.
Solubility Expression Test
E. coli was transformed with S. aureus BshC in pET28 according to “E. coli transformation”. A
starter culture was used to inoculate 200 mL of LB broth with 25 µg/ml kanamycin and grown
until the OD600 reached 0.6. Ni-NTA centrifugation chromatography was used to test protein
expression. A 1.02 g cell pellet was re-suspended in 4 mL lysis buffer. Five cycles of 30 sec. of
sonication lysed cells and a 100 µL sample of cell lysate was saved. Lysate was centrifuged 10

min 10,200 RPM at 4˚C and a 100 µL supernatant saved. Then, 1 mL of the supernatant was
placed in 4 separate 1.5 mL Eppendorf tubes with 200 µL of Ni-NTA resin. The resin was preequilibrated 3 times with 1 mL of lysis solution by centrifuging 2 min at 2,000 RPM 4˚C and
removing supernatant. The loaded supernatant was centrifuged 2 min at 2,000 RPM 4˚C.
Supernatant was discarded and 1 mL wash buffer added followed by 2 min centrifugation at
2000 RPM 4˚C. The wash step was repeated 3 time until close to negative on a Bradford spot
test. Then, 100 µL elution buffer was added to the tube and the tube centrifuged 2 min at 10,000
RPM 4˚C. The supernatant was then saved as eluate.
Protein Expression
About 50 µL of chemically competent E. coli cells of the BL-21 expression strain were
incubated on ice with 0.5-4 µL of pET-28 vector containing BshC S. aureus. The mixture rested
on ice 10 minutes and was heat shocked at 42°C for 90 seconds. After resting on ice for 6
minutes, the cells were allowed to recover with 250 µL LB shaking at 200RPM at 37°C for 1
hour and plated on LB media containing 25 mg/mL of kanamycin and grown overnight at 37°C.
Cells were grown in 25 µg/mL kanamycin LB media to 0.6 OD600. IPTG was used to induce
protein expression and the cells incubated at 16˚C overnight with shaking. Cells were harvested
by centrifugation at 5500 xg for 25 minutes and stored at -80˚C.
Ni-NTA Affinity Chromatography
Recombinant E. coli cells with BshC S. aureus protein expressed were re-suspended in lysis
buffer (20 mM HEPES pH 8, 300 mM NaCl, 10 mM Imidazole). EDTA at 0.5 mM and 0.5
mg/mL of lysozyme were added to digest the cells. MgCl2 at 5 mM and 5 µg/mL of DNAase
were added. The reaction was sonicated. Centrifugation at 17,000 xg for 25 minutes, 4°C was
used to isolate the supernatant which was then loaded onto a Pierce HisPur Ni-NTA column
equilibrated with lysis buffer. Bradford spot test was used to qualitatively test for the presence of
any protein in the column eluate. The column was washed until nearly Bradford negative with
wash buffer (20mM HEPES at pH 8, 300mM NaCl, 25mM Imidazole). Samples were then
collected, in a single collection vessel, by adding elution buffer (20mM HEPES at pH 8, 300mM
NaCl, 250mM Imidazole) to the column until nearly Bradford negative. The collected protein

fractions were dialyzed overnight in dialysis buffer, 20mM HEPES pH 7.5, 50mM NaCl. The
procedure was repeated for cell pellet of BshC from B. subtilus.

TEV Cleavage
To remove the hexa-histidine tag from the N-terminus of both BshC B. subtilus and BshC S.
aureus, his-tagged protein was dialyzed into Ni-NTA lysis buffer after purification. DTT to 0.5
mM and 1.5 mL of 0.7 mg/mL rTEV in 40% glycerol were added to the sample in dialysis
tubing. After dialyzing overnight at room temperature, the protein solution was run down a NiNTA column equilibrated with dialysis buffer and collected in fractions. Bradford spot test was
run on the flow-through and the column was eluted with 250 mM imidazole buffer after testing
nearly Bradford negative. Bradford was used to qualitatively determine purity and efficiency of
the TEV cleavage.
Protein Concentration Determination
Dialyzed protein was concentrated by centrifugation in Amicon Ultra-15 Centrifugal Filters and
the concentration checked by using a Cary 60 UV-Vis spectrophotometer. The absorbance at 280
nm was measured and the extinction coefficient of 55810 used in Beer’s law to determine
concentration. Concentrated BshC was frozen in liquid nitrogen and stored at -80°C.
SDS-PAGE
10% SDS-PAGE gels were made by using Amresco instructions and poured 0.75mm thin.
Samples of 40 µL from the solubility expression test were prepared for electrophoresis by
boiling for five minutes with 2X SDS-PAGE buffer (100 mM tris-HCL pH 6.8, 2%SDS, 4% βmercaptoethanol, 15% glycerol, 0.2 mg/mL bromothymol blue) in a 1:1 ratio. Electrophoresis
was run at 190 V, stained with Coomaissie brilliant blue, and destained with 10% MeOH and
10% AcOH in water. Purity was qualitatively assessed.
Crystallization Screens
Crystallization screens were set using the vapor diffusion hanging drop method with Hampton
Research Crystal Screen I and II as well as PEG Ion I and II. 400 µL of a condition was placed in

each well. A 12 mg/mL, 2 µL drop of BshC from S. aureus was pippeted on a cover slip and 2
µL of well solution added to the drop. The slip was inverted over the well with mineral oil
forming an air tight seal. Two drops were set up on each cover slip with either 5 mM AMP or
apo enzyme. Crystallization screens were also performed on his-tag cleaved BshC S. aureus in
5mM cysteine, 2mM BSH with 2mM DTT, or apo conditions.
Functional Analysis of BshC.
To qualitatively analyze BshC activity, Bacillus subtilus BshC was added to a BshC substrate
reaction containing. The substrate reaction contained 1mM UDP-glcNAc, 1 mM malate, 10 ug
BshA, and 10ug of BshB. After reacting for 2 hours at 37°C, 2 mM of cysteine and 5 uL of 2
mg/mL BshC were added to 200 uL assays. To each reaction tube 0.5 mM GTP, 0.5 mM CTP,
0.5 mM ATP, 0.5 mM serine with 0.5 mM ATP, no cysteine with 0.5 mM ATP, 100 uM zinc
with 0.5 mM ATP, or 0.5 mM NADH was added. These assay tubes were reacted at 37°C for 30
minutes. Chloroform extraction was performed and the upper aqueous layer saved for HPLC by
storing at -20°C. The process was repeated with S. aureus BshC with 0.5 mM ATP.

Results and Discussion
A

B

Figure 3. BshC B. subtilus ADP Binding Site Compared to PHYRE2 Model of BshC S. aureus. (A.)
Ribbon structure of B. subtilus (green) and model of S. aureus (blue) showing extra amino acids in side
loop. (B.) Superposition of the ADP binding site in B. subtilus structure (green) and S. aureus model
(magenta).

The PHYRE2 modeling server was used to generate a hypothetical model to predict interactions
in the BshC structure from S. aureus, specifically in the ADP binding site. The model reported a
confidence of 100%. Figure 3A shows a ribbon model of the predicted S. aureus model
superimposed on the actual B. subtilus structure. Two extra amino acids are present in the S.
aureus protein sequence which results in a larger loop over the ADP binding pocket. Figure 3B
depicts superposition of the ADP binding site in B. subtilus (green) and S. aureus (magenta).

Figure 4. Multiple sequence alignment of ADP binding pocket residues. The residues of the ADP
binding pocket in B. subtilis BshC are shown aligned with the BshC sequences of other Firmicutes.
Residues from the B. subtilis structure that make hydrogen bonding or π-stacking interactions with ADP
are indicated with a pound sign (#).

When the amino acid sequences of a few Bacillus species are aligned in Figure 4, it is found that
residues that interact with ADP are conserved. However, when the sequences of some
Staphylococcus species are aligned with the Bacillus species, they do not contain conserved

residues at the positions that interact with ADP (Figure 4). In Figure 3B, the binding pocket in B.
subtilus exhibits π-stacking interactions from W506 and Y510. The PHYRE2 model predicts
ADP interactions with the amino acid residues in BshC S. aureus. The S. aureus ADP binding
pocket is predicted to be dissimilar with Q509 present instead of Y510. The Q509 is not able to
facilitate π-stacking interactions like Y510 which suggests ADP may not bind as well, if at all.
Taken together, this information supports a hypothesis that BshC S. aureus might not have an
ADP binding site. Nevertheless, PHYRE2 only predicts the location of amino acid residues and
not their exact conformation. A crystal structure is necessary to determine the actual location of
the amino acid residues and how they interact with ADP.

Figure 5. Agarose gel of PCR from S. aureus genomic DNA. BshC was amplified by PCR from S.
aureus genomic DNA. Lane one contains a DNA ladder. Lane 2 contains PCR reaction of BshC gene
from S. aureus genomic DNA.

PCR product amplified from S. aureus genomic DNA was analyzed by agarose gel
electrophoresis. The molecular weight DNA ladder in lane one establishes standard MW to
determine fragment size. Using the MW ladder in lane one of Figure 5, the BshC gene product in
lane two was estimated to be about 1600 bp. This corresponds to the actual BshC gene size
suggesting PCR was successful. The small bands in lane two are most likely the 50 bp primers –
they just do not resolve well on the 1.5% agarose gel. The PCR product was subsequently

recovered from the gel slice and ligated into the pET-28 vector. E. coli cells were successfully
transformed with ligation reaction and plated on LB kanamycin plates to select for transformed
cells. Because of this, six different colonies were selected and grown overnight in LB kanamycin
and the cells miniprepped to isolate the pET-28 BshC vector.

Figure 6. Agarose gel of Plasmid Digestion. Lane one contains DNA ladder. Lane two contains negative
control. Lanes three through eight contain the digestion reactions of potential pET28 with BshC insert.

To determine if ligation of BshC into the pET-28 vector was successful, the plasmid DNA form
miniprepped cells was digested with XhoI and NheI restriction enzymes. The result, portrayed in
Figure 6, was that only the sample in lane five has BshC successfully ligated into pET-28. The
larger band in lane five is the pET-28 vector and the smaller one the gene insert.
The only successful BshC pET-28 vector was sent in for DNA sequencing to confirm the identity
of the DNA insert. Figure 7 displays the sequenced DNA aligned with the known sequence of
BshC S. aureus. The sequence alignment is almost identical, which is expected, except for a few
nucleotides near the end of the forward primer because sequencing gets less accurate after 900
bp. The reverse primer accurately overlaps those bases. The alignment confirms the BshC gene
was successfully inserted into pET-28. The chromatograms from both the forward and reverse
DNA sequencing reactions have been included in the appendix for reference.
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CGTGGGAATTCCCTCTGAATATTTTGTTTACTTTAAGAAGGAGATATACCATGGGCAGCA
-----------------------------------------------------------GCCATCCCTCNTCATCATCACAGCAGCGAGAACCTGTACTTCCAGGGCCATATGGCTAGC
-----------------------------------------------------------ATGGACTGTAAAGTAGTTAGTTTAAATGAAAAAGATCAGTTTATACCAAAAATAAAGAGC
ATGGACTGTAAAGTAGTTAGTTTAAATGAAAAAGATCAGTTTATACCAAAAATAAAGAGC
************************************************************
AGTGACCCTGTAATAACAGGATTATTTCAATATGATGCAGCTCAACAAACTAGTTTTGAA
AGTGACCCTGTAATAACAGGATTATTTCAATATGATGCAGCTCAACAAACTAGTTTTGAA
************************************************************
AAAAGGATGTCTAAAGAAAATAATGGAAGAGAAGCGGCATTAGCGAATGTTATTCGTGAA
AAAAGGATGTCTAAAGAAAATAATGGAAGAGAAGCGGCATTAGCGAATGTTATTCGTGAA
************************************************************
TATATGAGTGATTTAAAGCTTTCAAGTGAACAAGAATTAAACATACAACATTTAGCTAAT
TATATGAGTGATTTAAAGCTTTCAAGTGAACAAGAATTAAACATACAACATTTAGCTAAT
************************************************************
GGTTCAAAAGTTGTGATTGGTGGACAACAAGCAGGGCTTTTCGGGGGACCATTGTATACA
GGTTCAAAAGTTGTGATTGGTGGACAACAAGCAGGGCTTTTCGGGGGACCATTGTATACA
************************************************************
TTCCATAAAATATTTTCAATCATTACTTTATCTAAGGAATTAACGGATACACATAAGCAA
TTCCATAAAATATTTTCAATCATTACTTTATCTAAGGAATTAACGGATACACATAAGCAA
************************************************************
CAAGTAGTACCAGTTTTTTGGATTGCAGGAGAAGATCATGATTTCGATGAAGTGAATCAT
CAAGTAGTACCAGTTTTTTGGATTGCAGGAGAAGATCATGATTTCGATGAAGTGAATCAT
************************************************************
ACATTTGTTTATAACGAAAATCATGGGTCGCTGCATAAGGTTAAATATCATACAATGGAG
ACATTTGTTTATAACGAAAATCATGGGTCGCTGCATAAGGTTAAATATCATACAATGGAG
************************************************************
ATGCCAGAGACGACTGTCTCTAGATATTATCCTGATAAGGCTGAGTTGAAACAAACTTTA
ATGCCAGAGACGACTGTCTCTAGATATTATCCTGATAAGGCTGAGTTGAAACAAACTTTA
************************************************************
AAAACGATGTTCATTCATATGAAAGAAACTGTTCATACACAAGGTCTACTGGAGATTTGT
AAAACGATGTTCATTCATATGAAAGAAACTGTTCATACACAAGGTCTACTGGAGATTTGT
************************************************************
GACAGAATTATTGACCAATATGACTCGTGGACTGATATGTTTAAAGCACTACTGCATGAA
GACAGAATTATTGACCAATATGACTCGTGGACTGATATGTTTAAAGCACTACTGCATGAA
************************************************************
ACATTTAAAGCATATGGCGTTCTATTTATAGATGCGCAGTTTGAGCCGTTAAGAAAAATG
ACATTTAAAGCATATGGCGTTCTATTTATAGATGCGCAGTTTGAGCCGTTAAGAAAAATG
************************************************************
GAAGCGCCTATGTTTAAAAAGATTTTGAAAAAACATCAGTTGCTTGATGATGCTTTTAGA
GAAGCGCCTATGTTTAAAAAGATTTTGAAAAAACATCAGTTGCTTGATGATGCTTTTAGA
************************************************************
GCAACACANCAACGTACTCAAAATCAAGGCTTGAATGCGATGATACAAACAGATACAAAT
GCAACACAACAACGTACTCAAAATCAAGGCTTGAATGCGATGATACAAACAGATACAAAT
******** ***************************************************
GTTCATTTATTCTTTACATGATGAAAATATGCGTCAATTAGTTTCGTATGATGGTANGCN
GTTCATTTATTCTT-ACATGATGAAAATATGCGTCAATTAGTTTCGTATGATGGTAAGCA
************** ***************************************** **
TTTTAAATTAAATAAACCGGATA------------------------------------TTTTAAATTAAATAAAACAGATAAGACATATATAAAGGAAGAAATTATAAATATTGCGGA
**************** * ****
--------------------------------------GACCTTN--------------AAATCAACCTGAATTATTTTCTAATAATGTAGTGACAAGACCATTAATGGAAGAATGGTT
**** *
-----------------------------------------------------------ATTTAACACGGTGGCATTTGTTGGAGGACCGAGTGAAATTAAGTACTGGGCTGAACTAAA
-----------------------------------------------------------AGATGTATTTGAACTATTTGATGTTGAAATGCCTATCGTGATGCCAAGGCTTAGAATTAC
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CLUSTAL 2.1 multiple sequence alignment
BshCaureus
AAAACGATGTTCATTCATATGAAAGAAACTGTTCATACACAAGGTCTACTGGAGATTTGT
BshCRev
--------------CCAATATGACTCGNGGACTGATATGTTTAAAGCNCTACTGCNTGAA
BshCaureus
GACAGAATTATTGACCAATATGACTCGTGGACTGATATGTTTAAAGCACTACTGCATGAA
************* ******************* ******* ****
BshCRev
ACCATTTAAAGCATATGGCGTTCTATTTATAGATGCGCAGTTTGAGCCGTTAAGAAAAAT
BshCaureus
AC-ATTTAAAGCATATGGCGTTCTATTTATAGATGCGCAGTTTGAGCCGTTAAGAAAAAT
** *********************************************************
BshCRev
GGAAGCGCCTATGTTTAAAAAGATTTTGAAAAAACATCAGTTGCTTGATGATGCTTT-AG
BshCaureus
GGAAGCGCCTATGTTTAAAAAGATTTTGAAAAAACATCAGTTGCTTGATGATGCTTTTAG
********************************************************* **
BshCRev
AGCAACACAACAACGTACTCAAAATCAAGGCTTGAATGCGATGATACAAACAGATACAAA
BshCaureus
AGCAACACAACAACGTACTCAAAATCAAGGCTTGAATGCGATGATACAAACAGATACAAA
************************************************************
BshCRev
TGTTCATTTATTCTTACATGATGAAAATATGCGTCAATTAGTTTCGTATGATGGTAAGCA
BshCaureus
TGTTCATTTATTCTTACATGATGAAAATATGCGTCAATTAGTTTCGTATGATGGTAAGCA
************************************************************
BshCRev
TTTTAAATTAAATAAAACAGATAAGACATATATAAAGGAAGAAATTATAAATATTGCGGA
BshCaureus
TTTTAAATTAAATAAAACAGATAAGACATATATAAAGGAAGAAATTATAAATATTGCGGA
************************************************************
BshCRev
AAATCAACCTGAATTATTTTCTAATAATGTAGTGACAAGACCATTAATGGAAGAATGGTT
BshCaureus
AAATCAACCTGAATTATTTTCTAATAATGTAGTGACAAGACCATTAATGGAAGAATGGTT
************************************************************
BshCRev
ATTTAACACGGTGGCATTTGTTGGAGGACCGAGTGAAATTAAGTACTGGGCTGAACTAAA
BshCaureus
ATTTAACACGGTGGCATTTGTTGGAGGACCGAGTGAAATTAAGTACTGGGCTGAACTAAA
************************************************************
BshCRev
AGATGTATTTGAACTATTTGATGTTGAAATGCCTATCGTGATGCCAAGGCTTAGAATTAC
BshCaureus
AGATGTATTTGAACTATTTGATGTTGAAATGCCTATCGTGATGCCAAGGCTTAGAATTAC
************************************************************
BshCRev
TTATTTAAATGACCGTATAGAAAAATTACTTTCGAAATACAATATTCCATTAGAAAAAGT
BshCaureus
TTATTTAAATGACCGTATAGAAAAATTACTTTCGAAATACAATATTCCATTAGAAAAAGT
************************************************************
BshCRev
GTTAGTCGATGGTGTTGAAGGAGAAAGAAGTAAGTTTATTAGAGAACAAGCATCACATCA
BshCaureus
GTTAGTCGATGGTGTTGAAGGAGAAAGAAGTAAGTTTATTAGAGAACAAGCATCACATCA
************************************************************
BshCRev
ATTTATTGAAAAGGTAGAAGGTATGATTGAACAACAGCGTCGTCTAAACAAAGACTTATT
BshCaureus
ATTTATTGAAAAGGTAGAAGGTATGATTGAACAACAGCGTCGTCTAAACAAAGACTTATT
************************************************************
BshCRev
AGATGAAGTGGCGGGGAATCAAAATAATATTAACCTTGTGAATAAAAATAATGAAATTCA
BshCaureus
AGATGAAGTGGCGGGGAATCAAAATAATATTAACCTTGTGAATAAAAATAATGAAATTCA
************************************************************
BshCRev
TATACAACAGTATGATTATTTGTTAAAACGTTATCTTTTAAACATTGAAAGAGAAAACGA
BshCaureus
TATACAACAGTATGATTATTTGTTAAAACGTTATCTTTTAAACATTGAAAGAGAAAACGA
************************************************************
BshCRev
CATCAGTATGAAGCAATTTAGAGAAATTCAAGAAACACTCCATCCAATGGGAGGATTACA
BshCaureus
CATCAGTATGAAGCAATTTAGAGAAATTCAAGAAACACTCCATCCAATGGGAGGATTACA
************************************************************
BshCRev
AGAAAGAATATGGAATCCACTTCAAATTTTGAATGATTTTGGGACAGATGTGTTCAAGCC
BshCaureus
AGAAAGAATATGGAATCCACTTCAAATTTTGAATGATTTTGGGACAGATGTGTTCAAGCC
************************************************************
BshCRev
CTCCACCTATCCACCACTTTCTTACACTTTTGATCATATTATTATAAAACCTTAACTCGA
BshCaureus
CTCCACCTATCCACCACTTTCTTACACTTTTGATCATATTATTATAAAACCTTAA----*******************************************************
BshCRev
GCACCACCACCACCACCACTGAGATCCGGCTGCTACAAGCCCGAAGGAGNAG 1057
BshCaureus
----------------------------------------------------

46
660
106
719
165
779
225
839
285
899
345
959
405
1019
465
1079
525
1139
585
1199
645
1259
705
1319
765
1379
825
1439
885
1499
945
1559
1005
1614

Consensus key: * :single, fully conserved residue - : no consensus
Figure 7. Sequence Alignment of BshC S. aureus. Sequence of the PCR product was aligned to the
known WT sequence of S. aureus BshC using ClustalW for both the sequence from the T7 forward
primer and the complement of the sequence from the reverse primer.

Figure 8. BshC Solubility Expression SDS-PAGE. SDS-PAGE on small scale protein expression of
BshC S. aureus, and subsequent large scale, was used to assess expression, solubility, and purity.

Expression and purity of BshC protein was tested on a small scale and analyzed by SDS-PAGE
in Figure 8. The ladder is very faint in lanes 1 and 2 but MW bands are still legible. Lanes 5 and
6 show soluble proteins in the lysate and supernatant. Both of these lanes have many bands,
evidence of many different proteins present. Lane 7, however, only contains one band at 62kDa
which is the estimated MW of BshC S. aureus. BshC protein was successfully purified as
evidenced by the single band in lane 7. Lane 3 shows the result of affinity chromatography on a
large scale. It can be concluded that the protein is pure because there is such a strong signal of
BshC present when compared to the potential contaminating bands. Too much concentrated
protein was loaded and next time loading less volume would give a more accurate assessment of
purity. rTEV was successfully used to cleave the his-tag from the protein as determined
qualitatively by Bradford assay.
Despite a multitude of crystallization screens, no BshC S. aureus protein crystals have yet been
grown. At this point, no actual x-ray crystallographic data was able to be collected. Therefore,
the model predicted by PHYRE2 is currently the best model available. The idea that BshC from

S. aureus may not bind ADP is currently being tested by obtaining a crystal structure which
accurately reflects protein structure. In vitro assays of BshC B. subtilis were analyzed by HPLC
analysis with substrates cysteine, glucosaminyl-malate, and either ATP, CTP, GTP, NADH, Zn2+
with ATP, or serine with ATP. Assays were also performed on BshC S. aureus with cysteine,
glucosaminyl-malate, and ATP. The results did not reveal any enzyme activity. The HPLC trace
for BshC with NADH had an unidentifiable peak detected at 4.681 minutes. Future work is
needed to characterize this finding. Employing x-ray crystallography to understand how the
structure of BshC dictates its function will allow specific inhibitors to be designed that stop
bacillithiol biosynthesis. The absence of bacillithiol will allow fosfomycin to be re-established as
an effective antibiotic once again.
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Appendix

Supplemental Figure 1. Chromatogram from Forward Primer. Chromatogram produced by DNA
sequencing PCR product with the T7 forward primer.

Supplemental Figure 2. Chromatogram from Reverse Primer. Chromatogram produced by DNA
sequencing PCR product for the reverse primer.

